Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, et al.
JAMA Network Open (2024) Vol. 7, Iss. 2, pp. e2354991-e2354991
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
Anne F. Luetkemeyer, Kara W. Chew, Stuart R. Lacey, et al.
Clinical Infectious Diseases (2025)
Open Access | Times Cited: 1
Treating Acute Covid-19 — Final Chapters Still Unwritten
Rajesh T. Gandhi, Martin Hirsch
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1234-1236
Open Access | Times Cited: 12
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19
Takahiro Takazono, Satoki Fujita, Takuji Komeda, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 8, pp. 1821-1833
Open Access | Times Cited: 10
Ensitrelvir Fumaric Acid: First Approval
Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 6, pp. 721-728
Closed Access | Times Cited: 8
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned
Roy M. Gulick, Alice K. Pau, Eric S. Daar, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 11, pp. 1547-1557
Closed Access | Times Cited: 8
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
Hongzhou Lu, George Zhang, John Mao, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102582-102582
Open Access | Times Cited: 5
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Phrutsamon Wongnak, William HK Schilling, Podjanee Jittamala, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. 953-963
Open Access | Times Cited: 5
Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial
Takeki Uehara, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.
Antiviral Research (2025), pp. 106097-106097
Open Access
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population
Ataru Igarashi, Kenji Kurazono, Naoya Itsumura, et al.
Journal of Medical Economics (2025), pp. 1-13
Open Access
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Targeting the SARS-CoV-2 reservoir in long COVID
Amy D. Proal, Soo Aleman, Morgane Bomsel, et al.
The Lancet Infectious Diseases (2025)
Closed Access
Real-World Treatment Outcomes in the First and Subsequent Coronavirus Disease 2019 (COVID-19) Hospital Clusters
Yoshinobu Ohsaki, Takaaki Sasaki, Yasuhiro Umekage, et al.
Cureus (2025)
Open Access
Antiviral Trials—Navigating the Shifting Sands of a Pandemic
Beatrice Sim, Cameron R. Wolfe
Clinical Infectious Diseases (2025)
Closed Access
Comparative Study of Ensitrelvir and Symptomatic Therapy in Healthcare Workers with Mild COVID-19: A Single Center Retrospective Analysis in Chiba, Japan.
Jun Hirai, Yuki Hanai
Journal of Infection and Chemotherapy (2025), pp. 102668-102668
Closed Access
The time to return-to-work in healthcare workers with COVID-19 treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2: An observational study utilizing pre-existing data from a single hospital
Makoto Katsuta, Masatoshi Kitazono, Noriyuki Nagai, et al.
Journal of Infection and Chemotherapy (2025), pp. 102669-102669
Open Access
Hospital Preparedness for Conducting Clinical Research During a Pandemic: A Nationwide Survey Among Designated Medical Institutions for Infectious Diseases in Japan
Kazuaki Jindai, Hiroki Saito, Eriko Morino, et al.
Health Security (2025)
Closed Access
Analysis of risk factors for long COVID after mild COVID-19 during the Omicron wave in Japan
Hotaka Namie, Takahiro Takazono, Rina Kawasaki, et al.
Respiratory Investigation (2025) Vol. 63, Iss. 3, pp. 303-310
Closed Access
Influence of Educational Films on Antiviral Prescription for COVID-19: Insights from Web-Based Survey in Japan
Kosaku Komiya, Akihiko Hagiwara, Yuichiro Shindo, et al.
Antibiotics (2025) Vol. 14, Iss. 3, pp. 276-276
Open Access
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, et al.
Antiviral Research (2024) Vol. 229, pp. 105958-105958
Open Access | Times Cited: 4
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Eric A. Meyerowitz, Yijia Li
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. 908-917
Open Access | Times Cited: 8
Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study
Ryohei Yoshida, Takaaki Sasaki, Yoshinobu Ohsaki
Cureus (2024)
Open Access | Times Cited: 2
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19
Kanal Singh, Joseph M. Rocco, Véronique Nussenblatt
Seminars in Hematology (2024) Vol. 61, Iss. 5, pp. 321-332
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top